Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders

Qing Ma, Barry S. Zingman, Amneris E. Luque, Margaret A. Fischl, Barbara M. Gripshover, Charles S. Venuto, Robin DiFrancesco, Alan Forrest, Gene D. Morse

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Achieving targeted antiretroviral (ARV) plasma concentrations during long-term treatment in human immunodeficiency virus (HIV)-infected patients with substance-related disorders (SRDs) may be challenging due to a number of factors, including medication adherence, coinfection with hepatitis B or C virus, medication intolerance, and drug interactions. One approach to investigate these factors is to conduct therapeutic drug monitoring to measure ARVexposure during treatment. The objective of this study was to utilize therapeutic drug monitoring to compare efavirenz (EFV) and protease inhibitor pharmacokinetics in patients with and without SRDs. Methods: This was a multicenter, cross-sectional open-label study in patients with HIV-1 infection receiving antiretroviral therapy (ART), with active (n = 129) or without (n = 146) SRD according to National Institute on Drug Abuse criteria. Two hundred seventy-five subjects who were receiving either protease inhibitor-based or EFVbased ART regimens for .6 months were enrolled at 4 HIV treatment centers with an equal distribution of SRD and non-SRD at each site. The patients were instructed during enrollment visits with regard to the importance of adherence before and after study visits. Demographics and routine clinical laboratory tests were recorded. Results: Among the 275 patients, 47% had SRD with at least 1 substance. There were no significant differences between SRD and non-SRD groups for race, gender, age, or CD4 count at entry. A significantly higher proportion of patients with SRD had an entry HIV RNA plasma concentration .75 copies per milliliter compared with patients without SRD (40% vs 28%, P = 0.044). Logistic regression modeling revealed an association between HIV RNA plasma concentration and African American race (P = 0.017). A significantly higher proportion of SRDs also had an EFV or protease inhibitor trough concentration below the desired range (23% vs 9%, P = 0.048). Significantly lower trough concentrations were noted in patients with SRDs receiving atazanavir (0.290 vs 0.976 mg/mL) or lopinavir (3.75 vs 5.30 mg/mL). Conclusions: The pharmacokinetic data indicate differences between HIV-infected patients with and without SRDs that may influence viral load suppression during long-term ART. These findings require additional investigation in a randomized design with more intensive pharmacokinetic assessment to identify individual factors that are contributing to suboptimal ARV exposure in patients with SRDs.

Original languageEnglish (US)
Pages (from-to)309-314
Number of pages6
JournalTherapeutic Drug Monitoring
Volume33
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

efavirenz
Drug Monitoring
Protease Inhibitors
Substance-Related Disorders
HIV
Pharmacokinetics
National Institute on Drug Abuse (U.S.)
Therapeutics
RNA
Lopinavir

Keywords

  • Antiretroviral therapy
  • Substance-related disorders
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. / Ma, Qing; Zingman, Barry S.; Luque, Amneris E.; Fischl, Margaret A.; Gripshover, Barbara M.; Venuto, Charles S.; DiFrancesco, Robin; Forrest, Alan; Morse, Gene D.

In: Therapeutic Drug Monitoring, Vol. 33, No. 3, 06.2011, p. 309-314.

Research output: Contribution to journalArticle

Ma, Qing ; Zingman, Barry S. ; Luque, Amneris E. ; Fischl, Margaret A. ; Gripshover, Barbara M. ; Venuto, Charles S. ; DiFrancesco, Robin ; Forrest, Alan ; Morse, Gene D. / Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. In: Therapeutic Drug Monitoring. 2011 ; Vol. 33, No. 3. pp. 309-314.
@article{a5ae4531059f47c2be1f6e1b1428a3d9,
title = "Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders",
abstract = "Background: Achieving targeted antiretroviral (ARV) plasma concentrations during long-term treatment in human immunodeficiency virus (HIV)-infected patients with substance-related disorders (SRDs) may be challenging due to a number of factors, including medication adherence, coinfection with hepatitis B or C virus, medication intolerance, and drug interactions. One approach to investigate these factors is to conduct therapeutic drug monitoring to measure ARVexposure during treatment. The objective of this study was to utilize therapeutic drug monitoring to compare efavirenz (EFV) and protease inhibitor pharmacokinetics in patients with and without SRDs. Methods: This was a multicenter, cross-sectional open-label study in patients with HIV-1 infection receiving antiretroviral therapy (ART), with active (n = 129) or without (n = 146) SRD according to National Institute on Drug Abuse criteria. Two hundred seventy-five subjects who were receiving either protease inhibitor-based or EFVbased ART regimens for .6 months were enrolled at 4 HIV treatment centers with an equal distribution of SRD and non-SRD at each site. The patients were instructed during enrollment visits with regard to the importance of adherence before and after study visits. Demographics and routine clinical laboratory tests were recorded. Results: Among the 275 patients, 47{\%} had SRD with at least 1 substance. There were no significant differences between SRD and non-SRD groups for race, gender, age, or CD4 count at entry. A significantly higher proportion of patients with SRD had an entry HIV RNA plasma concentration .75 copies per milliliter compared with patients without SRD (40{\%} vs 28{\%}, P = 0.044). Logistic regression modeling revealed an association between HIV RNA plasma concentration and African American race (P = 0.017). A significantly higher proportion of SRDs also had an EFV or protease inhibitor trough concentration below the desired range (23{\%} vs 9{\%}, P = 0.048). Significantly lower trough concentrations were noted in patients with SRDs receiving atazanavir (0.290 vs 0.976 mg/mL) or lopinavir (3.75 vs 5.30 mg/mL). Conclusions: The pharmacokinetic data indicate differences between HIV-infected patients with and without SRDs that may influence viral load suppression during long-term ART. These findings require additional investigation in a randomized design with more intensive pharmacokinetic assessment to identify individual factors that are contributing to suboptimal ARV exposure in patients with SRDs.",
keywords = "Antiretroviral therapy, Substance-related disorders, Therapeutic drug monitoring",
author = "Qing Ma and Zingman, {Barry S.} and Luque, {Amneris E.} and Fischl, {Margaret A.} and Gripshover, {Barbara M.} and Venuto, {Charles S.} and Robin DiFrancesco and Alan Forrest and Morse, {Gene D.}",
year = "2011",
month = "6",
doi = "10.1097/FTD.0b013e31821d3adb",
language = "English (US)",
volume = "33",
pages = "309--314",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders

AU - Ma, Qing

AU - Zingman, Barry S.

AU - Luque, Amneris E.

AU - Fischl, Margaret A.

AU - Gripshover, Barbara M.

AU - Venuto, Charles S.

AU - DiFrancesco, Robin

AU - Forrest, Alan

AU - Morse, Gene D.

PY - 2011/6

Y1 - 2011/6

N2 - Background: Achieving targeted antiretroviral (ARV) plasma concentrations during long-term treatment in human immunodeficiency virus (HIV)-infected patients with substance-related disorders (SRDs) may be challenging due to a number of factors, including medication adherence, coinfection with hepatitis B or C virus, medication intolerance, and drug interactions. One approach to investigate these factors is to conduct therapeutic drug monitoring to measure ARVexposure during treatment. The objective of this study was to utilize therapeutic drug monitoring to compare efavirenz (EFV) and protease inhibitor pharmacokinetics in patients with and without SRDs. Methods: This was a multicenter, cross-sectional open-label study in patients with HIV-1 infection receiving antiretroviral therapy (ART), with active (n = 129) or without (n = 146) SRD according to National Institute on Drug Abuse criteria. Two hundred seventy-five subjects who were receiving either protease inhibitor-based or EFVbased ART regimens for .6 months were enrolled at 4 HIV treatment centers with an equal distribution of SRD and non-SRD at each site. The patients were instructed during enrollment visits with regard to the importance of adherence before and after study visits. Demographics and routine clinical laboratory tests were recorded. Results: Among the 275 patients, 47% had SRD with at least 1 substance. There were no significant differences between SRD and non-SRD groups for race, gender, age, or CD4 count at entry. A significantly higher proportion of patients with SRD had an entry HIV RNA plasma concentration .75 copies per milliliter compared with patients without SRD (40% vs 28%, P = 0.044). Logistic regression modeling revealed an association between HIV RNA plasma concentration and African American race (P = 0.017). A significantly higher proportion of SRDs also had an EFV or protease inhibitor trough concentration below the desired range (23% vs 9%, P = 0.048). Significantly lower trough concentrations were noted in patients with SRDs receiving atazanavir (0.290 vs 0.976 mg/mL) or lopinavir (3.75 vs 5.30 mg/mL). Conclusions: The pharmacokinetic data indicate differences between HIV-infected patients with and without SRDs that may influence viral load suppression during long-term ART. These findings require additional investigation in a randomized design with more intensive pharmacokinetic assessment to identify individual factors that are contributing to suboptimal ARV exposure in patients with SRDs.

AB - Background: Achieving targeted antiretroviral (ARV) plasma concentrations during long-term treatment in human immunodeficiency virus (HIV)-infected patients with substance-related disorders (SRDs) may be challenging due to a number of factors, including medication adherence, coinfection with hepatitis B or C virus, medication intolerance, and drug interactions. One approach to investigate these factors is to conduct therapeutic drug monitoring to measure ARVexposure during treatment. The objective of this study was to utilize therapeutic drug monitoring to compare efavirenz (EFV) and protease inhibitor pharmacokinetics in patients with and without SRDs. Methods: This was a multicenter, cross-sectional open-label study in patients with HIV-1 infection receiving antiretroviral therapy (ART), with active (n = 129) or without (n = 146) SRD according to National Institute on Drug Abuse criteria. Two hundred seventy-five subjects who were receiving either protease inhibitor-based or EFVbased ART regimens for .6 months were enrolled at 4 HIV treatment centers with an equal distribution of SRD and non-SRD at each site. The patients were instructed during enrollment visits with regard to the importance of adherence before and after study visits. Demographics and routine clinical laboratory tests were recorded. Results: Among the 275 patients, 47% had SRD with at least 1 substance. There were no significant differences between SRD and non-SRD groups for race, gender, age, or CD4 count at entry. A significantly higher proportion of patients with SRD had an entry HIV RNA plasma concentration .75 copies per milliliter compared with patients without SRD (40% vs 28%, P = 0.044). Logistic regression modeling revealed an association between HIV RNA plasma concentration and African American race (P = 0.017). A significantly higher proportion of SRDs also had an EFV or protease inhibitor trough concentration below the desired range (23% vs 9%, P = 0.048). Significantly lower trough concentrations were noted in patients with SRDs receiving atazanavir (0.290 vs 0.976 mg/mL) or lopinavir (3.75 vs 5.30 mg/mL). Conclusions: The pharmacokinetic data indicate differences between HIV-infected patients with and without SRDs that may influence viral load suppression during long-term ART. These findings require additional investigation in a randomized design with more intensive pharmacokinetic assessment to identify individual factors that are contributing to suboptimal ARV exposure in patients with SRDs.

KW - Antiretroviral therapy

KW - Substance-related disorders

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=80051793349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051793349&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31821d3adb

DO - 10.1097/FTD.0b013e31821d3adb

M3 - Article

VL - 33

SP - 309

EP - 314

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -